A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer
Key
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival
6 months from the start of treatment
No
Michael J Morris, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
TOP205
NCT01296243
February 2011
February 2015
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
The Cancer Institute of New Jersey | New Brunswick, New Jersey 08901 |
University of Michigan Health System | Ann Arbor, Michigan |
University of Wisconsin Carbone Cancer Center | Madison, Wisconsin 53792-5669 |